Akebia Therapeutics Inc - Company Profile

Powered by

All the data and insights you need on Akebia Therapeutics Inc in one report.

$195 $295
Buy Report View Sample
  • Save hours of research time and resources with
    our up-to-date Akebia Therapeutics Inc Strategy Report

  • Understand Akebia Therapeutics Inc position in the market,
    performance and strategic initiatives.

  • Gain competitive edge and increase your
    chances of success

Back to companies

Akebia Therapeutics Inc: Overview

Select Item

Akebia Therapeutics Inc (Akebia Therapeutics) is a commercial-stage biopharmaceutical company. It develops and commercializes novel therapeutics based on hypoxia-inducible factors for patients with kidney disease and other metabolic disorders. The company’s product portfolio includes vadadustat, a hypoxia-inducible factor (HIF) prolyl hydroxylase that treats dialysis-dependent chronic kidney disease (DD-CKD) and non-dialysis-dependent chronic kidney disease (NDD-CKD); ferric citrate targeting hyperphosphatemia and iron deficiency anemia; AKB-9090 for acute kidney injury and acute respiratory distress syndrome; and AKB-10108, that treats retinopathy of prematurity. It operates through its subsidiaries in the US, Ireland and the UK. Akebia Therapeutics is headquartered in Cambridge, Massachusetts, the US.

 Gain a 360-degree view of Akebia Therapeutics Inc and make more informed decisions for your business Gain a 360-degree view of Akebia Therapeutics Inc and make more informed decisions for your business Find out more
Headquarters United States of America
Address Suite 1400, 245 First Street, Cambridge, Massachusetts, 02142
Website www.akebia.com
Telephone 1 617 8712098
No of Employees 167
Industry Pharmaceuticals and Healthcare
Ticker Symbol & Exchange AKBA (NASD)
Revenue (2022) $194.6M -33.5% (2022 vs 2021)
EPS XYZ
Net Income (2022) XYZ 44.9% (2022 vs 2021)
Market Cap* $305.7M
Net Profit Margin (2022) XYZ 17.2% (2022 vs 2021)
* As of and is in US$
View Akebia Therapeutics Inc financials
Gain access to our premium signals and make informed decisions for your business Gain access to our premium signals and make informed decisions for your business Find out more

Akebia Therapeutics Inc premium industry data and analytics

70+

Clinical Trials

Determine Akebia Therapeutics Inc go-to-market proposition and gain insight into the company’s clinical operations, recruitment, and trial strategy.

50+

Catalyst Calendar

Proactively evaluate Akebia Therapeutics Inc’s catalyst impacts to stay ahead of the competition & improve corporate planning. Bolster business development with timely opportunities.

40+

Lead Sheet

Understand when and why to target accounts of prospective leads, as well as who to reach out to, drawing on intelligence for Akebia Therapeutics Inc’s relevant decision makers and contact details.

30+

Insights

Remove risk and uncertainty, gain a competitive edge and secure actionable leads with access to company-related investigative journalist content.

20+

Pipeline Drugs

Identify which of Akebia Therapeutics Inc’s products will be commercialized, helping you to better contend with shifting product portfolios, and allowing you to stay one step ahead of the market.

3

Regulatory Milestones

Track drug and patent expiries along with geographies impacted.

2

Sales & Consensus Forecasts

Understand the current and future drug revenue for Akebia Therapeutics Inc and assess market opportunity for new entrants with patient population 8-year forecasts.

2

Marketed Drugs

Understand Akebia Therapeutics Inc’s commercialized product portfolio to stay one step ahead of the market.

1

ICT Spend & Tech Priorities

IT Client Prospector provides intelligence on Akebia Therapeutics Inc’s likely spend across technology areas enabling you to understand the digital strategy.

Products and Services

Products Brands
Vadadustat: Auryxia
Dialysis-Dependent Chronic Kidney Disease Vafseo
Non-Dialysis Dependent Chronic Kidney Disease Akebia Therapeutics
XYZ
XYZ
XYZ
Understand Akebia Therapeutics Inc portfolio and identify potential areas for collaboration Understand Akebia Therapeutics Inc portfolio and identify potential areas for collaboration Find out more

History

History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.

Year Event Description
2024 Financing Agreements In January, the company secured US$55 million loan from funds and accounts managed by BlackRock.
2023 Regulatory Approval In June, the company announced that Swiss Agency for Therapeutic Products granted marketing authorization for Vafseo.
2023 Contracts/Agreements In May, the company entered into an agreement with MEDICE Arzneimittel Pütter GmbH&Co.KG for the commercialization of Vafseo for the treatment of anemia associated with CKD in Europe and Australia.
Dive into past operations, including product releases, deals, acquisitions & more Dive into past operations, including product releases, deals, acquisitions & more Find out more
Image for loader

Competitor Comparison

Key Parameters Akebia Therapeutics Inc Johnson & Johnson Pfizer Inc Sanofi GSK plc
Headquarters United States of America United States of America United States of America France United Kingdom
City Cambridge New Brunswick New York Paris Brentford
State/Province Massachusetts New Jersey New York Ile-de-France England
No. of Employees 167 131,900 88,000 87,994 70,212
Entity Type Public Public Public Public Public
Benchmark the company against the market with exclusive information on key competitors Benchmark the company against the market with exclusive information on key competitors Find out more
Chart Financial activity with access to more key stats Chart Financial activity with access to more key stats Find out more
Executives
Name Position Board Since Age
Adrian Adams Chairman Executive Board - 73
John P. Butler Director; President; Chief Executive Officer Executive Board 2013 59
Michel Dahan Chief Operating Officer; Senior Vice President Senior Management 2013 45
Nicole R. Hadas Secretary; Senior Vice President; Chief Legal Officer Senior Management 2013 51
Meredith Bowman Senior Vice President - People; Chief People Officer Senior Management 2016 -
Non Dignissim Eros Proin vel Convallis 2024 XY
Non Dignissim Eros Proin vel Convallis 2024 XY
Non Dignissim Eros Proin vel Convallis 2024 XY
Gain insight into Akebia Therapeutics Inc key executives to enhance your sales strategy Gain insight into Akebia Therapeutics Inc key executives to enhance your sales strategy Find out more
Still looking?

Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.

Explorer

Access more premium companies when you subscribe to Explorer

Get in touch about GlobalData Company reports

Contact the team or request a demo to find out how our data can drive your business forward